1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Apellis’ Empaveli Data In Frontline PNH Incremental, But Still Helpful

Data Could Aid Uptake Despite Already Broad Label

 
• By Alaric DeArment

While the drug appears more efficacious than Alexion’s C5 inhibitors, those drugs could prove difficult to dethrone given how entrenched they are in PNH therapy.

Render illustration of Clinical Trial title on medical documents
Results of Apellis' PRINCE study of Empaveli seen as having incremental benefit for already-approved drug • Source: Shutterstock

Phase III data for Apellis Pharmaceuticals, Inc.’s C3 inhibitor Empaveli (pegcetacoplan) in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) appear to offer a largely incremental benefit for the drug given that its broad label already includes such patients. Nevertheless, the data are expected to help with the drug’s uptake, though Alexion Pharmaceuticals Inc.’s C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are sufficiently entrenched that they could prove difficult to unseat despite Empaveli showing what appears to be better efficacy.

The Waltham, MA-based Apellis and Stockholm-based Swedish Orphan Biovitrum AB (Sobi) announced on 25 May topline results from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.